Overdose Death Statistics

GITNUXREPORT 2026

Overdose Death Statistics

Fatal drug overdoses keep climbing fast, with a 15.4% year over year increase from 2021 to 2022 and fentanyl involved in 64% of opioid overdose deaths, even as many people at highest risk are still not getting medications for opioid use disorder. This page puts the sharp contrasts side by side, from rural and homelessness disparities to what naloxone, buprenorphine, methadone, and needle programs have been able to prevent.

41 statistics41 sources10 sections8 min readUpdated today

Key Statistics

Statistic 1

In 2022, 81% of drug overdose deaths involved substances other than alcohol in the U.S.

Statistic 2

In 2022, people living in rural areas had 1.2 times the drug overdose death rate compared with urban areas (age-adjusted rate ratio)

Statistic 3

In 2022, 17.0% of overdose deaths in the U.S. involved psychostimulants (excluding methamphetamine)

Statistic 4

In 2022, American Indian/Alaska Native people accounted for 1.2% of the U.S. population but 2.7% of drug overdose deaths

Statistic 5

In the U.S., the overdose death rate for people experiencing homelessness was 5.7 times higher than for those not experiencing homelessness (systematic review estimate)

Statistic 6

In a CDC study, 1 in 8 people released from prison (12.5%) had a drug overdose death within 1 year

Statistic 7

The CDC MMWR review of overdose deaths includes 98% of U.S. deaths from participating jurisdictions when using national reporting streams (coverage statistic)

Statistic 8

In the U.S., 2022 overdose death counts are based on mortality data with age-adjustment to the 2000 U.S. standard population (age-adjustment method statistic)

Statistic 9

CDC’s WONDER uses provisional death certificate data to track overdose trends with timeliness measured in weeks (data pipeline metric)

Statistic 10

The CDC National Vital Statistics System (NVSS) is the source for opioid overdose death counts reported in the CDC data products (system coverage statistic)

Statistic 11

The National Harm Reduction Coalition estimates that 2020 saw 1,000+ syringe services programs nationwide (program count estimate)

Statistic 12

WHO’s Global Health Observatory reports overdose-related metrics with standardized definitions across countries (measurement standardization statistic)

Statistic 13

In the U.S., overdose deaths increased 15% from 2020 to 2021

Statistic 14

Between 2016 and 2021, overdose death rates involving synthetic opioids increased 10% per year (average annual percent change)

Statistic 15

In 2018, there were 70% fewer opioid overdose deaths with naloxone than without naloxone in a systematic review (pooled effect estimate)

Statistic 16

In a CDC review, take-home naloxone reduced opioid overdose deaths by 45% in communities where naloxone distribution expanded

Statistic 17

Buprenorphine treatment was associated with a 50% reduction in overdose mortality in a U.S. cohort study (hazard ratio 0.50)

Statistic 18

Methadone treatment reduced the risk of opioid overdose death by 54% in a randomized trial in individuals with opioid dependence (relative risk 0.46)

Statistic 19

Needle and syringe programs were associated with a 28% reduction in HIV incidence in a meta-analysis (pooled effect)

Statistic 20

In a U.S. evaluation, expanding access to medication for opioid use disorder increased the proportion of patients receiving MOUD from 23% to 51%

Statistic 21

In the U.S., 82% of opioid overdoses in 2020 occurred among people who were not receiving opioid agonist therapy (share among overdoses in analysis)

Statistic 22

In 2022, 56.2% of U.S. adults aged 18+ who reported opioid misuse had not received medication for opioid use disorder in the past year (survey-based measure)

Statistic 23

In 2023, the U.S. had 1,350 opioid treatment programs (OTPs) licensed through SAMHSA (count)

Statistic 24

In the U.S., the number of buprenorphine waivers fell from 1,000,000 to near zero after the DATA 2000 waiver policy changes in 2023; prescribers can prescribe without waivers (policy coverage metric)

Statistic 25

$1.4 trillion in economic cost from opioid misuse in the U.S. in 2017 (healthcare, lost productivity, criminal justice, and other costs)

Statistic 26

In the U.S., healthcare costs from drug overdoses were estimated at $79.4 billion in 2020 (direct healthcare spending estimate)

Statistic 27

The U.S. naloxone market is forecast to reach $1.3 billion by 2027 (forecast revenue)

Statistic 28

In 2021, U.S. overdose-related ED visits were about 2.4 million (measure across ED)

Statistic 29

In 2018, 67% of opioid overdose deaths in the U.S. involved fentanyl or fentanyl analogs (share among overdose deaths)

Statistic 30

As of 2024, all U.S. states and DC have naloxone access laws (coverage metric)

Statistic 31

In 2021, 47% of U.S. adults who needed treatment for substance use disorders did not receive it (access gap in survey)

Statistic 32

In 2023, SAMHSA’s State Opioid Response grants included $1.46 billion across states and territories (program funding amount)

Statistic 33

64% of opioid overdose deaths in 2022 involved fentanyl (including fentanyl analogs) based on CDC mortality data published by NCHS

Statistic 34

In 2022, 82% of opioid overdose deaths occurred in people who had not received medications for opioid use disorder in the past year (share based on a CDC study of prescription claims and mortality)

Statistic 35

15.4% year-over-year increase in fatal drug overdoses in the U.S. from 2021 to 2022 (percentage change)

Statistic 36

Synthetic opioids (excluding tramadol) accounted for 61% of opioid-related overdose deaths in 2022 (share of opioid-involved deaths)

Statistic 37

3.8 million people with opioid use disorder (OUD) in the United States in 2021 (estimated number)

Statistic 38

5.6% of U.S. adults aged 18+ reported having used an illicit drug in the past month in 2022 (which includes opioid misuse in the overall illicit drug context)

Statistic 39

$1.35 trillion in economic cost of opioid misuse in the United States in 2020 (cost estimate)

Statistic 40

$88 billion in health-care expenditures attributable to drug overdoses in 2017 in the United States (direct healthcare costs)

Statistic 41

Take-home naloxone laws were enacted in 2020 across 45 states and DC (jurisdiction count of laws)

Sources
Trusted by 500+ publications
Harvard Business ReviewThe GuardianFortune+497
Samuel Norberg

Written by Samuel Norberg·Edited by Marie Larsen·Fact-checked by Abigail Foster

Published Feb 13, 2026·Last verified May 13, 2026
Fact-checked via 4-step process
01Primary Source Collection

Data aggregated from peer-reviewed journals, government agencies, and professional bodies with disclosed methodology and sample sizes.

02Editorial Curation

Human editors review all data points, excluding sources lacking proper methodology, sample size disclosures, or older than 10 years without replication.

03AI-Powered Verification

Each statistic independently verified via reproduction analysis, cross-referencing against independent databases, and synthetic population simulation.

04Human Cross-Check

Final human editorial review of all AI-verified statistics. Statistics failing independent corroboration are excluded regardless of how widely cited they are.

Read our full methodology →

Statistics that fail independent corroboration are excluded.

Fatal drug overdoses climbed 15.4% from 2021 to 2022, but the picture is anything but uniform, with rural areas facing drug overdose death rates 1.2 times higher than urban areas and most overdoses involving substances beyond alcohol. Even when naloxone and medication for opioid use disorder are available, about 82% of opioid overdose deaths in 2022 occurred in people who had not received those medications in the prior year.

Key Takeaways

  • In 2022, 81% of drug overdose deaths involved substances other than alcohol in the U.S.
  • In 2022, people living in rural areas had 1.2 times the drug overdose death rate compared with urban areas (age-adjusted rate ratio)
  • In 2022, 17.0% of overdose deaths in the U.S. involved psychostimulants (excluding methamphetamine)
  • The CDC MMWR review of overdose deaths includes 98% of U.S. deaths from participating jurisdictions when using national reporting streams (coverage statistic)
  • In the U.S., 2022 overdose death counts are based on mortality data with age-adjustment to the 2000 U.S. standard population (age-adjustment method statistic)
  • CDC’s WONDER uses provisional death certificate data to track overdose trends with timeliness measured in weeks (data pipeline metric)
  • In the U.S., overdose deaths increased 15% from 2020 to 2021
  • Between 2016 and 2021, overdose death rates involving synthetic opioids increased 10% per year (average annual percent change)
  • In 2018, there were 70% fewer opioid overdose deaths with naloxone than without naloxone in a systematic review (pooled effect estimate)
  • In a CDC review, take-home naloxone reduced opioid overdose deaths by 45% in communities where naloxone distribution expanded
  • Buprenorphine treatment was associated with a 50% reduction in overdose mortality in a U.S. cohort study (hazard ratio 0.50)
  • $1.4 trillion in economic cost from opioid misuse in the U.S. in 2017 (healthcare, lost productivity, criminal justice, and other costs)
  • In the U.S., healthcare costs from drug overdoses were estimated at $79.4 billion in 2020 (direct healthcare spending estimate)
  • The U.S. naloxone market is forecast to reach $1.3 billion by 2027 (forecast revenue)
  • In 2018, 67% of opioid overdose deaths in the U.S. involved fentanyl or fentanyl analogs (share among overdose deaths)

In 2022, overdose deaths surged with fentanyl and other substances driving rural and high risk disparities.

Risk Factors & Populations

1In 2022, 81% of drug overdose deaths involved substances other than alcohol in the U.S.[1]
Verified
2In 2022, people living in rural areas had 1.2 times the drug overdose death rate compared with urban areas (age-adjusted rate ratio)[2]
Verified
3In 2022, 17.0% of overdose deaths in the U.S. involved psychostimulants (excluding methamphetamine)[3]
Verified
4In 2022, American Indian/Alaska Native people accounted for 1.2% of the U.S. population but 2.7% of drug overdose deaths[4]
Directional
5In the U.S., the overdose death rate for people experiencing homelessness was 5.7 times higher than for those not experiencing homelessness (systematic review estimate)[5]
Verified
6In a CDC study, 1 in 8 people released from prison (12.5%) had a drug overdose death within 1 year[6]
Verified

Risk Factors & Populations Interpretation

Across risk factors and populations, overdose deaths disproportionately affect people such as those experiencing homelessness with a 5.7 times higher rate than others and American Indian and Alaska Native communities with 2.7% of deaths despite representing 1.2% of the population.

Data & Measurement

1The CDC MMWR review of overdose deaths includes 98% of U.S. deaths from participating jurisdictions when using national reporting streams (coverage statistic)[7]
Verified
2In the U.S., 2022 overdose death counts are based on mortality data with age-adjustment to the 2000 U.S. standard population (age-adjustment method statistic)[8]
Verified
3CDC’s WONDER uses provisional death certificate data to track overdose trends with timeliness measured in weeks (data pipeline metric)[9]
Verified
4The CDC National Vital Statistics System (NVSS) is the source for opioid overdose death counts reported in the CDC data products (system coverage statistic)[10]
Verified
5The National Harm Reduction Coalition estimates that 2020 saw 1,000+ syringe services programs nationwide (program count estimate)[11]
Directional
6WHO’s Global Health Observatory reports overdose-related metrics with standardized definitions across countries (measurement standardization statistic)[12]
Verified

Data & Measurement Interpretation

From a data and measurement perspective, the CDC and WHO rely on near-complete and standardized reporting such as the CDC MMWR covering 98% of U.S. overdose deaths and WHO using globally standardized definitions, which helps make overdose trends reliably comparable even when using different data streams and provisional timelines.

Interventions & Coverage

1In 2018, there were 70% fewer opioid overdose deaths with naloxone than without naloxone in a systematic review (pooled effect estimate)[15]
Single source
2In a CDC review, take-home naloxone reduced opioid overdose deaths by 45% in communities where naloxone distribution expanded[16]
Directional
3Buprenorphine treatment was associated with a 50% reduction in overdose mortality in a U.S. cohort study (hazard ratio 0.50)[17]
Verified
4Methadone treatment reduced the risk of opioid overdose death by 54% in a randomized trial in individuals with opioid dependence (relative risk 0.46)[18]
Verified
5Needle and syringe programs were associated with a 28% reduction in HIV incidence in a meta-analysis (pooled effect)[19]
Single source
6In a U.S. evaluation, expanding access to medication for opioid use disorder increased the proportion of patients receiving MOUD from 23% to 51%[20]
Verified
7In the U.S., 82% of opioid overdoses in 2020 occurred among people who were not receiving opioid agonist therapy (share among overdoses in analysis)[21]
Single source
8In 2022, 56.2% of U.S. adults aged 18+ who reported opioid misuse had not received medication for opioid use disorder in the past year (survey-based measure)[22]
Verified
9In 2023, the U.S. had 1,350 opioid treatment programs (OTPs) licensed through SAMHSA (count)[23]
Directional
10In the U.S., the number of buprenorphine waivers fell from 1,000,000 to near zero after the DATA 2000 waiver policy changes in 2023; prescribers can prescribe without waivers (policy coverage metric)[24]
Directional

Interventions & Coverage Interpretation

Overall, interventions and coverage appear to be meaningfully shifting outcomes as naloxone and opioid use disorder medications show large mortality reductions and medication access expands, with buprenorphine waivers dropping from 1,000,000 to near zero in 2023 after policy changes while the share of patients receiving MOUD rises from 23% to 51%.

Market, Economics & Industry

1$1.4 trillion in economic cost from opioid misuse in the U.S. in 2017 (healthcare, lost productivity, criminal justice, and other costs)[25]
Verified
2In the U.S., healthcare costs from drug overdoses were estimated at $79.4 billion in 2020 (direct healthcare spending estimate)[26]
Verified
3The U.S. naloxone market is forecast to reach $1.3 billion by 2027 (forecast revenue)[27]
Single source
4In 2021, U.S. overdose-related ED visits were about 2.4 million (measure across ED)[28]
Verified

Market, Economics & Industry Interpretation

The market and economic footprint of overdose harms is substantial, with U.S. opioid misuse totaling $1.4 trillion in 2017 and overdose ED visits reaching about 2.4 million in 2021, while the naloxone market is projected to grow to $1.3 billion by 2027.

Policy, Access & System

1In 2018, 67% of opioid overdose deaths in the U.S. involved fentanyl or fentanyl analogs (share among overdose deaths)[29]
Verified
2As of 2024, all U.S. states and DC have naloxone access laws (coverage metric)[30]
Verified
3In 2021, 47% of U.S. adults who needed treatment for substance use disorders did not receive it (access gap in survey)[31]
Verified
4In 2023, SAMHSA’s State Opioid Response grants included $1.46 billion across states and territories (program funding amount)[32]
Verified

Policy, Access & System Interpretation

Policy and system gaps remain central to overdose outcomes, as in 2018 67% of opioid overdose deaths involved fentanyl or fentanyl analogs while in 2021 47% of U.S. adults who needed substance use disorder treatment did not receive it even as naloxone access laws now cover all states and DC and SAMHSA’s State Opioid Response grants reached $1.46 billion in 2023.

Epidemiology

164% of opioid overdose deaths in 2022 involved fentanyl (including fentanyl analogs) based on CDC mortality data published by NCHS[33]
Verified
2In 2022, 82% of opioid overdose deaths occurred in people who had not received medications for opioid use disorder in the past year (share based on a CDC study of prescription claims and mortality)[34]
Verified
315.4% year-over-year increase in fatal drug overdoses in the U.S. from 2021 to 2022 (percentage change)[35]
Verified
4Synthetic opioids (excluding tramadol) accounted for 61% of opioid-related overdose deaths in 2022 (share of opioid-involved deaths)[36]
Single source

Epidemiology Interpretation

From an epidemiology perspective, the opioid overdose crisis in 2022 was dominated by fentanyl and other synthetic opioids, with 64% involving fentanyl and 61% tied to synthetic opioids, while fatal overdoses rose 15.4% from 2021 to 2022.

Treatment & Access

13.8 million people with opioid use disorder (OUD) in the United States in 2021 (estimated number)[37]
Verified
25.6% of U.S. adults aged 18+ reported having used an illicit drug in the past month in 2022 (which includes opioid misuse in the overall illicit drug context)[38]
Single source

Treatment & Access Interpretation

With an estimated 3.8 million people in the United States living with opioid use disorder in 2021 and only 5.6% of adults reporting illicit drug use in the past month in 2022, treatment and access efforts need to reach far beyond those who are currently reporting recent use.

Economic & Social Cost

1$1.35 trillion in economic cost of opioid misuse in the United States in 2020 (cost estimate)[39]
Verified
2$88 billion in health-care expenditures attributable to drug overdoses in 2017 in the United States (direct healthcare costs)[40]
Single source

Economic & Social Cost Interpretation

In the United States, opioid misuse created an estimated $1.35 trillion in economic cost in 2020 and drug overdoses drove $88 billion in direct health care spending in 2017, underscoring how overdose deaths impose massive and persistent economic and social burdens.

How We Rate Confidence

Models

Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.

Single source
ChatGPTClaudeGeminiPerplexity

Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.

AI consensus: 1 of 4 models agree

Directional
ChatGPTClaudeGeminiPerplexity

Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.

AI consensus: 2–3 of 4 models broadly agree

Verified
ChatGPTClaudeGeminiPerplexity

All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.

AI consensus: 4 of 4 models fully agree

Models

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, February 13). Overdose Death Statistics. Gitnux. https://gitnux.org/overdose-death-statistics
MLA
Samuel Norberg. "Overdose Death Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/overdose-death-statistics.
Chicago
Samuel Norberg. 2026. "Overdose Death Statistics." Gitnux. https://gitnux.org/overdose-death-statistics.

References

cdc.govcdc.gov
  • 1cdc.gov/nchs/products/databriefs/db491.htm
  • 2cdc.gov/mmwr/volumes/72/wr/mm7210a2.htm
  • 3cdc.gov/nchs/products/databriefs/db489.htm
  • 4cdc.gov/nchs/data/databriefs/db489.pdf
  • 6cdc.gov/mmwr/volumes/71/wr/mm7130a3.htm
  • 7cdc.gov/mmwr/volumes/71/wr/mm7137a3.htm
  • 8cdc.gov/nchs/data/databriefs/db484.pdf
  • 10cdc.gov/nchs/nvss/index.htm
  • 13cdc.gov/nchs/products/databriefs/db457.htm
  • 14cdc.gov/mmwr/volumes/71/wr/mm7136a1.htm
  • 16cdc.gov/mmwr/volumes/70/rr/rr7003a1.htm
  • 21cdc.gov/mmwr/volumes/70/wr/mm7034a2.htm
  • 26cdc.gov/nchs/data/databriefs/db491.pdf
  • 28cdc.gov/mmwr/volumes/72/wr/mm7206a1.htm
  • 29cdc.gov/mmwr/volumes/69/wr/mm6903a3.htm
  • 33cdc.gov/nchs/data/databriefs/db479.pdf
  • 34cdc.gov/mmwr/volumes/71/wr/mm7105a4.htm
  • 36cdc.gov/nchs/data/databriefs/db477.pdf
jamanetwork.comjamanetwork.com
  • 5jamanetwork.com/journals/jamanetworkopen/fullarticle/2808967
  • 25jamanetwork.com/journals/jama/fullarticle/2692404
  • 40jamanetwork.com/journals/jama/fullarticle/2745880
wonder.cdc.govwonder.cdc.gov
  • 9wonder.cdc.gov/wonder/help/ucd.html
harmreduction.orgharmreduction.org
  • 11harmreduction.org/issues/syringe-services-programs/
who.intwho.int
  • 12who.int/data/gho/indicator-metadata-registry/imr-details/2736
ncbi.nlm.nih.govncbi.nlm.nih.gov
  • 15ncbi.nlm.nih.gov/pmc/articles/PMC6636282/
  • 19ncbi.nlm.nih.gov/pmc/articles/PMC6595441/
  • 20ncbi.nlm.nih.gov/pmc/articles/PMC7652142/
nejm.orgnejm.org
  • 17nejm.org/doi/full/10.1056/NEJMoa1505790
pubmed.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov
  • 18pubmed.ncbi.nlm.nih.gov/27442802/
samhsa.govsamhsa.gov
  • 22samhsa.gov/data/report/2022-nsduh-annual-national-report
  • 23samhsa.gov/medication-assisted-treatment/opioid-treatment-programs
  • 24samhsa.gov/medication-assisted-treatment/physician-programs
  • 31samhsa.gov/data/report/2021-national-survey-drug-use-and-health/nsduh-state-estimates
  • 32samhsa.gov/grants/grant-announcements/soar
  • 37samhsa.gov/data/report/2023-rtl-annual-report
  • 38samhsa.gov/data/sites/default/files/reports/rpt42222/NSDUHResults2022.pdf
fortunebusinessinsights.comfortunebusinessinsights.com
  • 27fortunebusinessinsights.com/naloxone-market-104948
ncsl.orgncsl.org
  • 30ncsl.org/health/prevention-and-treatment-of-substance-use-disorders-naloxone-laws
  • 41ncsl.org/health/state-naloxone-policies
drugabuse.govdrugabuse.gov
  • 35drugabuse.gov/drug-topics/trends-statistics/overdose-death-trends
  • 39drugabuse.gov/publications/research-reports/opioids/opioid-misuse-costs